SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells.

Resistance to chemotherapy is the major cause of cancer treatment failure. Insight into the mechanism of action of agents that modulate multidrug resistance (MDR) is instrumental for the design of more effective treatment modalities. Here we show, using KB-V-1 MDR human epidermoid carcinoma cells and [3H]palmitic acid as metabolic tracer, that the MDR modulator SDZ PSC 833 (PSC 833) activates ceramide synthesis. In a short time course experiment, ceramide was generated as early as 15 min (40% increase) after the addition of PSC 833 (5.0 microM), and by 3 h, [3H]ceramide was >3-fold that of control cells. A 24-h dose-response experiment showed that at 1.0 and 10 microM PSC 833, ceramide levels were 2.5- and 13.6-fold higher, respectively, than in untreated cells. Concomitant with the increase in cellular ceramide was a progressive decrease in cell survival, suggesting that ceramide elicited a cytotoxic response. Analysis of DNA in cells treated with PSC 833 showed oligonucleosomal DNA fragmentation, characteristic of apoptosis. The inclusion of fumonisin B1, a ceramide synthase inhibitor, blocked PSC 833-induced ceramide generation. Assessment of ceramide mass by TLC lipid charring confirmed that PSC 833 markedly enhanced ceramide synthesis, not only in KB-V-1 cells but also in wild-type KB-3-1 cells. The capacity of PSC 833 to reverse drug resistance was demonstrated with vinblastine. Whereas each agent at a concentration of 1.0 microM reduced cell survival by approximately 20%, when PSC 833 and vinblastine were coadministered, cell viability fell to zero. In parallel experiments measuring ceramide metabolism, it was shown that the PSC 833/vinblastine combination synergistically increased cellular ceramide levels. Vinblastine toxicity, also intensified by PSC 833 in wild-type KB-3-1 cells, was as well accompanied by enhanced ceramide formation. These data demonstrate that PSC 833 has mechanisms of action in addition to P-glycoprotein chemotherapy efflux pumping.

[1]  A. Giuliano,et al.  The multidrug resistance modulator SDZ PSC 833 is a potent activator of cellular ceramide formation , 1998, FEBS letters.

[2]  J. Jaffrezou,et al.  Restoration of TNF‐α‐induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P‐glycoprotein blocker PSC833 , 1998 .

[3]  G. Laurent,et al.  Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  A. Giuliano,et al.  Glucosylceramide: a marker for multiple-drug resistant cancers. , 1998, Anticancer research.

[5]  M. Manfait,et al.  Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance , 1997, Leukemia.

[6]  F. Sharom,et al.  Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter. , 1997, Biochemical pharmacology.

[7]  E. Estey,et al.  Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Gottschalk,et al.  Anti-immunoglobulin-induced Apoptosis in WEHI 231 Cells Involves the Slow Formation of Ceramide from Sphingomyelin and Is Blocked by bcl-xL* , 1997, The Journal of Biological Chemistry.

[9]  S. Chouaib,et al.  Alteration of the Sphingomyelin/Ceramide Pathway Is Associated with Resistance of Human Breast Carcinoma MCF7 Cells to Tumor Necrosis Factor-α-mediated Cytotoxicity* , 1997, The Journal of Biological Chemistry.

[10]  Y. Shao,et al.  Mutually co-operative interactions between modulators of P-glycoprotein. , 1997, Biochimica et biophysica acta.

[11]  J. Saunders,et al.  Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. , 1997, Anti-cancer drugs.

[12]  A. Giuliano,et al.  Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells* , 1997, The Journal of Biological Chemistry.

[13]  M. J. Newman,et al.  The reversal of multidrug resistance in multicellular tumor spheroids by SDZ PSC 833. , 1997, Anticancer research.

[14]  L. Obeid,et al.  Mechanisms of ceramide-mediated apoptosis. , 1997, Advances in experimental medicine and biology.

[15]  P. Sonneveld,et al.  Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. , 1996, Leukemia.

[16]  A. Giuliano,et al.  Tamoxifen retards glycosphingolipid metabolism in human cancer cells , 1996, FEBS letters.

[17]  A. Dantzig,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. , 1996, Cancer research.

[18]  A E Giuliano,et al.  Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells* , 1996, The Journal of Biological Chemistry.

[19]  T. Tsuruo,et al.  Potentiation of the reversal activity of SDZ PSC833 on multi‐drug resistance by an anti‐p‐glycoprotein monoclonal antibody MRK‐16 , 1996, International journal of cancer.

[20]  J. Jaffrezou,et al.  Daunorubicin‐induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. , 1996, The EMBO journal.

[21]  S. Grant,et al.  Induction of Apoptosis and Potentiation of Ceramide-mediated Cytotoxicity by Sphingoid Bases in Human Myeloid Leukemia Cells (*) , 1996, The Journal of Biological Chemistry.

[22]  M. D’Incalci,et al.  Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. , 1996, British Journal of Cancer.

[23]  K. Scotto,et al.  Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals , 1995, Cell.

[24]  S. Froidevaux,et al.  Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice. , 1995, Toxicology.

[25]  D. Cohen,et al.  Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. , 1995, Oncology research.

[26]  S. Nayfield.  Tamoxifen's role in chemoprevention of breast cancer: An update , 1995, Journal of cellular biochemistry. Supplement.

[27]  R. Testi,et al.  Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase , 1994, The Journal of experimental medicine.

[28]  C. Potten,et al.  Apoptosis and cancer chemotherapy. , 1994, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[29]  A. Haimovitz-Friedman,et al.  Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis , 1994, The Journal of experimental medicine.

[30]  A. Harris,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. , 1994, Biochemical pharmacology.

[31]  R. Perry,et al.  Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance. , 1994, Cancer research.

[32]  S. Grant,et al.  Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[34]  M. Volm,et al.  Expression of resistance factors (P‐glycoprotein, glutathione S‐transferase‐π, and topoisomerase II) and their interrelationship to proto‐oncogene products in renal cell carcinomas , 1993, Cancer.

[35]  M. Gottesman.  How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. , 1993, Cancer research.

[36]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[37]  N. Bleehen,et al.  Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A , 1991 .

[38]  G. Laurent,et al.  Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein. , 1991, The Journal of biological chemistry.

[39]  C. Gavériaux.  SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier , 1991 .

[40]  N. Bleehen,et al.  Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. , 1991, European journal of cancer.

[41]  J. Baak,et al.  Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. , 1989, Journal of the National Cancer Institute.

[42]  S. Gupta,et al.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. , 1986, The Journal of clinical investigation.

[43]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[44]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.